Singapore Clinical Research Institute

The Singapore Clinical Research Institute (SCRI) is the national coordinating body for clinical trials with a vision to establish Singapore as a regional thought leader in clinical research.  This is accomplished through the deployment of innovative technologies and processes, and strategic coordination of ecosystem capabilities and infrastructure to achieve synergies that will enhance the clinical research ecosystem aimed towards a healthier community and better patient outcomes.

SCRI has broad experience in the fast-growing therapeutic fields of haematology and oncology, having partnered up and supported numerous clinical studies in myeloma, liver cancer, lung cancer and ovarian cancer.

SCRI is a business unit under the Consortium for Clinical Research and Innovation, Singapore (CRIS), a subsidiary of Ministry of Health Holdings (MOHH).

SCRI also collaborates with clinicians to enhance Singapore’s clinical research ecosystem and strengthen its expertise in executing multi-site, multi-national studies and the development of regional clinical research networks.

For more information, visit

www.scri.edu.sg

LinkedIn:

https://www.linkedin.com/company/singaporeclinicalresearchinstitute/